These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26769666)

  • 1. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE.
    Hinrichs JB; Shin HO; Kaercher D; Hasdemir D; Murray T; Kaireit T; Lutat C; Vogel A; Meyer BC; Wacker FK; Rodt T
    Eur Radiol; 2016 Oct; 26(10):3447-55. PubMed ID: 26769666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.
    Nörthen A; Asendorf T; Shin HO; Hinrichs JB; Werncke T; Vogel A; Kirstein MM; Wacker FK; Rodt T
    Abdom Radiol (NY); 2018 Dec; 43(12):3288-3300. PubMed ID: 29680967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
    Choi SJ; Kim J; Seo J; Kim HS; Lee JM; Park H
    Abdom Imaging; 2014 Jun; 39(3):518-25. PubMed ID: 24519566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.
    Najmi Varzaneh F; Pandey A; Aliyari Ghasabeh M; Shao N; Khoshpouri P; Pandey P; Zarghampour M; Fouladi D; Liddell R; Anders RA; Kamel IR
    Eur Radiol; 2018 Jul; 28(7):3032-3040. PubMed ID: 29383518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization.
    Choi SJ; Kim J; Seo J; Kim HS; Lee JM; Park H
    Eur Radiol; 2016 Jan; 26(1):225-34. PubMed ID: 25991485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed Tomography Perfusion Following Transarterial Chemoembolization of Hepatocellular Carcinoma: A Feasibility Study in the Early Period.
    Wimmer T; Steiner J; Talakic E; Stauber R; Quehenberger F; Portugaller RH; Schoellnast H
    J Comput Assist Tomogr; 2017; 41(5):708-712. PubMed ID: 28296685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Choi SJ; Kim J; Kim HS; Park H
    Abdom Radiol (NY); 2017 Jul; 42(7):1871-1879. PubMed ID: 28204855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
    Luedemann WM; Geisel D; Gebauer B; Schnapauff D; Chapiro J; Wieners G; Steffen I; Kahn J
    Eur Radiol; 2020 Mar; 30(3):1601-1608. PubMed ID: 31811428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
    Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ
    Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response.
    Dioguardi Burgio M; Sartoris R; Libotean C; Zappa M; Sibert A; Vilgrain V; Ronot M
    Cancer Imaging; 2019 Nov; 19(1):75. PubMed ID: 31730491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma response to transcatheter arterial chemoembolisation using automatically generated pre-therapeutic tumour volumes by a random forest-based segmentation protocol.
    Khalaf AM; Fuentes D; Morshid A; Kaseb AO; Hassan M; Hazle JD; Elsayes KM
    Clin Radiol; 2019 Dec; 74(12):974.e13-974.e20. PubMed ID: 31521326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
    Chen G; Ma DQ; He W; Zhang BF; Zhao LQ
    World J Gastroenterol; 2008 Oct; 14(37):5738-43. PubMed ID: 18837093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Langenbach MC; Vogl TJ; Said G; Scholtz JE; Hammerstingl R; Gruber-Rouh T
    Cancer Biother Radiopharm; 2024 Apr; 39(3):196-202. PubMed ID: 33481646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.